Stryker Co. (NYSE:SYK) has been given an average recommendation of “Hold” by the twenty-two brokerages that are currently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $134.79.

Several equities analysts have recently weighed in on the stock. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Stryker in a report on Monday. BidaskClub lowered shares of Stryker from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 13th. Citigroup Inc. upped their price objective on shares of Stryker from $114.00 to $125.00 and gave the company a “sell” rating in a report on Friday, June 9th. BMO Capital Markets reiterated a “hold” rating and set a $125.00 price objective on shares of Stryker in a report on Tuesday, April 11th. Finally, Barclays PLC reiterated a “sell” rating and set a $133.00 price objective on shares of Stryker in a report on Thursday, April 27th.

Shares of Stryker (NYSE:SYK) traded down 0.60% on Monday, reaching $141.38. The company’s stock had a trading volume of 1,307,168 shares. Stryker has a 52-week low of $106.48 and a 52-week high of $145.62. The firm has a 50 day moving average of $138.95 and a 200 day moving average of $128.75. The company has a market cap of $52.84 billion, a PE ratio of 31.77 and a beta of 0.81.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, April 25th. The medical technology company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.43 by $0.05. Stryker had a net margin of 15.03% and a return on equity of 18.50%. The firm had revenue of $2.96 billion for the quarter, compared to analyst estimates of $2.90 billion. During the same quarter in the prior year, the business earned $1.24 earnings per share. The business’s quarterly revenue was up 18.4% compared to the same quarter last year. Analysts predict that Stryker will post $6.43 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, July 31st. Stockholders of record on Friday, June 30th will be given a dividend of $0.425 per share. This represents a $1.70 dividend on an annualized basis and a dividend yield of 1.20%. The ex-dividend date is Wednesday, June 28th. Stryker’s dividend payout ratio is currently 38.20%.

TRADEMARK VIOLATION WARNING: “Stryker Co. (SYK) Given Average Recommendation of “Hold” by Analysts” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/06/19/stryker-co-syk-given-average-recommendation-of-hold-by-analysts.html.

In other news, insider David Floyd sold 7,381 shares of the stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $144.70, for a total transaction of $1,068,030.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Timothy J. Scannell sold 13,322 shares of the stock in a transaction that occurred on Tuesday, May 2nd. The shares were sold at an average price of $135.89, for a total transaction of $1,810,326.58. The disclosure for this sale can be found here. 7.40% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Personal Capital Advisors Corp bought a new position in Stryker during the first quarter worth $267,000. Asset Management One Co. Ltd. increased its position in Stryker by 1,227.6% in the fourth quarter. Asset Management One Co. Ltd. now owns 601,118 shares of the medical technology company’s stock worth $72,060,000 after buying an additional 555,841 shares in the last quarter. Aviva PLC increased its position in Stryker by 20.9% in the fourth quarter. Aviva PLC now owns 246,275 shares of the medical technology company’s stock worth $29,519,000 after buying an additional 42,537 shares in the last quarter. Massmutual Trust Co. FSB ADV bought a new position in Stryker during the fourth quarter worth $3,069,000. Finally, Dimensional Fund Advisors LP increased its position in Stryker by 3.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 602,507 shares of the medical technology company’s stock worth $72,189,000 after buying an additional 19,584 shares in the last quarter. 74.26% of the stock is owned by hedge funds and other institutional investors.

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Receive News & Ratings for Stryker Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Co. and related companies with MarketBeat.com's FREE daily email newsletter.